OTCMKTS:PHMMF

Pharma Mar Competitors

$111.00
-1.50 (-1.33 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$109.81
Now: $111.00
$111.00
50-Day Range
$111.50
MA: $118.62
$138.00
52-Week Range
$55.80
Now: $111.00
$158.75
Volume582 shs
Average Volume1,331 shs
Market Capitalization$2.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.11

Competitors

Pharma Mar (OTCMKTS:PHMMF) Vs. NNCHY, ATDRY, ALNPY, HKMPF, AEXAY, and BKGFY

Should you be buying PHMMF stock or one of its competitors? Companies in the industry of "private households" are considered alternatives and competitors to Pharma Mar, including Nissan Chemical (NNCHY), Auto Trader Group (ATDRY), ANA (ALNPY), Hikma Pharmaceuticals (HKMPF), Atos (AEXAY), and The Berkeley Group (BKGFY).

Nissan Chemical (OTCMKTS:NNCHY) and Pharma Mar (OTCMKTS:PHMMF) are both mid-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Nissan Chemical and Pharma Mar, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nissan Chemical01102.50
Pharma Mar01002.00

Risk & Volatility

Nissan Chemical has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500.

Profitability

This table compares Nissan Chemical and Pharma Mar's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nissan Chemical14.72%15.49%12.17%
Pharma MarN/AN/AN/A

Earnings & Valuation

This table compares Nissan Chemical and Pharma Mar's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nissan Chemical$1.90 billion4.06$283.18 million$1.8728.49
Pharma Mar$96.12 million21.29$-12,740,000.00($0.48)-231.25

Nissan Chemical has higher revenue and earnings than Pharma Mar. Pharma Mar is trading at a lower price-to-earnings ratio than Nissan Chemical, indicating that it is currently the more affordable of the two stocks.

Summary

Nissan Chemical beats Pharma Mar on 10 of the 11 factors compared between the two stocks.

Pharma Mar (OTCMKTS:PHMMF) and Auto Trader Group (OTCMKTS:ATDRY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharma Mar and Auto Trader Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharma Mar01002.00
Auto Trader Group14502.40

Risk and Volatility

Pharma Mar has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Auto Trader Group has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Insider and Institutional Ownership

0.1% of Auto Trader Group shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Pharma Mar and Auto Trader Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharma MarN/AN/AN/A
Auto Trader GroupN/AN/AN/A

Earnings and Valuation

This table compares Pharma Mar and Auto Trader Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharma Mar$96.12 million21.29$-12,740,000.00($0.48)-231.25
Auto Trader Group$469.02 million16.82$260.76 millionN/AN/A

Auto Trader Group has higher revenue and earnings than Pharma Mar.

Summary

Auto Trader Group beats Pharma Mar on 6 of the 7 factors compared between the two stocks.

Pharma Mar (OTCMKTS:PHMMF) and ANA (OTCMKTS:ALNPY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharma Mar and ANA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharma Mar01002.00
ANA00103.00

Risk and Volatility

Pharma Mar has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, ANA has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Profitability

This table compares Pharma Mar and ANA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharma MarN/AN/AN/A
ANA-18.16%-20.38%-7.66%

Earnings and Valuation

This table compares Pharma Mar and ANA's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharma Mar$96.12 million21.29$-12,740,000.00($0.48)-231.25
ANA$18.13 billion0.41$254.43 millionN/AN/A

ANA has higher revenue and earnings than Pharma Mar.

Summary

ANA beats Pharma Mar on 6 of the 10 factors compared between the two stocks.

Pharma Mar (OTCMKTS:PHMMF) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Risk and Volatility

Pharma Mar has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharma Mar and Hikma Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharma Mar01002.00
Hikma Pharmaceuticals01502.83

Earnings and Valuation

This table compares Pharma Mar and Hikma Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharma Mar$96.12 million21.29$-12,740,000.00($0.48)-231.25
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00

Hikma Pharmaceuticals has higher revenue and earnings than Pharma Mar. Pharma Mar is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pharma Mar and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharma MarN/AN/AN/A
Hikma PharmaceuticalsN/AN/AN/A

Summary

Hikma Pharmaceuticals beats Pharma Mar on 7 of the 8 factors compared between the two stocks.

Atos (OTCMKTS:AEXAY) and Pharma Mar (OTCMKTS:PHMMF) are both mid-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

0.1% of Atos shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Atos and Pharma Mar, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atos16302.20
Pharma Mar01002.00

Earnings and Valuation

This table compares Atos and Pharma Mar's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atos$12.98 billion0.58$3.81 billionN/AN/A
Pharma Mar$96.12 million21.29$-12,740,000.00($0.48)-231.25

Atos has higher revenue and earnings than Pharma Mar.

Volatility & Risk

Atos has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Profitability

This table compares Atos and Pharma Mar's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtosN/AN/AN/A
Pharma MarN/AN/AN/A

Summary

Atos beats Pharma Mar on 6 of the 7 factors compared between the two stocks.

The Berkeley Group (OTCMKTS:BKGFY) and Pharma Mar (OTCMKTS:PHMMF) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Risk & Volatility

The Berkeley Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Earnings and Valuation

This table compares The Berkeley Group and Pharma Mar's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Berkeley Group$2.43 billion3.25$519.43 million$3.9716.38
Pharma Mar$96.12 million21.29$-12,740,000.00($0.48)-231.25

The Berkeley Group has higher revenue and earnings than Pharma Mar. Pharma Mar is trading at a lower price-to-earnings ratio than The Berkeley Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for The Berkeley Group and Pharma Mar, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Berkeley Group34302.00
Pharma Mar01002.00

Profitability

This table compares The Berkeley Group and Pharma Mar's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Berkeley GroupN/AN/AN/A
Pharma MarN/AN/AN/A

Summary

The Berkeley Group beats Pharma Mar on 6 of the 7 factors compared between the two stocks.


Pharma Mar Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nissan Chemical logo
NNCHY
Nissan Chemical
1.0$53.27-4.8%$8.09 billion$1.90 billion30.09Gap Up
Auto Trader Group logo
ATDRY
Auto Trader Group
0.7$2.04-2.0%$8.04 billion$469.02 million0.00Gap Up
ANA logo
ALNPY
ANA
0.6$4.24-4.5%$8.02 billion$18.13 billion-3.50Upcoming Earnings
Hikma Pharmaceuticals logo
HKMPF
Hikma Pharmaceuticals
1.3$33.00-0.0%$8.00 billion$2.21 billion22.00Decrease in Short Interest
News Coverage
Atos logo
AEXAY
Atos
0.7$13.76-6.0%$7.99 billion$12.98 billion0.00Gap Up
The Berkeley Group logo
BKGFY
The Berkeley Group
1.3$65.04-0.0%$7.91 billion$2.43 billion16.38
Voestalpine logo
VLPNY
Voestalpine
0.7$8.86-0.0%$7.91 billion$14.14 billion-11.97
HEGIY
Hengan International Group
1.1$33.45-0.6%$7.89 billion$3.25 billion14.05
Aurora Cannabis logo
ACBFF
Aurora Cannabis
0.5$8.19-3.8%$7.87 billionN/A0.00
B&M European Value Retail logo
BMRRY
B&M European Value Retail
0.9$31.79-0.5%$7.73 billion$4.85 billion30.86
Commerzbank logo
CRZBY
Commerzbank
0.9$5.85-4.4%$7.65 billion$13.98 billion9.91Gap Up
Just Eat logo
JSTTY
Just Eat
0.3$11.10-5.4%$7.55 billion$1.04 billion0.00Gap Down
Keppel logo
KPELY
Keppel
0.9$8.26-2.0%$7.51 billion$5.56 billion-63.53
JFE logo
JFEEF
JFE
0.6$12.63-2.2%$7.43 billion$34.31 billion-2.35Increase in Short Interest
Square Enix logo
SQNXF
Square Enix
0.9$62.01-0.9%$7.39 billion$2.40 billion30.25
Fuchs Petrolub logo
FUPBY
Fuchs Petrolub
0.9$13.12-1.3%$7.39 billionN/A0.00
SJM logo
SJMHF
SJM
0.5$1.25-3.8%$7.36 billion$4.32 billion0.00Gap Up
BJINY
BEIJING ENTPS H/S
1.3$57.62-0.0%$7.27 billion$7.38 billion8.24
The Weir Group logo
WEGRY
The Weir Group
0.8$13.90-0.3%$7.24 billion$3.40 billion24.81Analyst Upgrade
News Coverage
Raiffeisen Bank International logo
RAIFY
Raiffeisen Bank International
0.6$5.41-1.3%$7.21 billion$5.85 billion0.00Dividend Cut
News Coverage
TravelSky Technology logo
TSYHY
TravelSky Technology
0.0$24.16-1.1%$7.15 billion$1.18 billion0.00
Royal Mail logo
ROYMY
Royal Mail
1.0$13.93-1.7%$7.08 billion$13.79 billion33.98
HTCMY
Hitachi Construction Machinery
1.2$63.52-0.0%$6.83 billion$8.59 billion45.37
Japan Airlines logo
JAPSY
Japan Airlines
0.6$9.63-4.3%$6.77 billion$12.98 billion-4.38Increase in Short Interest
British Land logo
BTLCY
British Land
1.3$7.09-2.5%$6.74 billion$785.11 million0.00Analyst Report
MonotaRO logo
MONOY
MonotaRO
1.1$26.38-1.9%$6.73 billion$1.21 billion58.62Upcoming Earnings
Analyst Upgrade
Gap Down
Dai Nippon Printing logo
DNPLY
Dai Nippon Printing
0.8$10.01-3.6%$6.72 billion$12.90 billion83.42Gap Up
SWEDISH ORPHAN/S logo
SWTUY
SWEDISH ORPHAN/S
0.4$24.38-1.2%$6.64 billion$763.19 million48.76
GRSXY
Grasim Industries
0.7$14.00-0.0%$6.54 billion$10.48 billion0.00High Trading Volume
The Bank of East Asia logo
BKEAY
The Bank of East Asia
1.8$2.06-8.7%$6.53 billion$4.13 billion18.73Gap Down
Shimizu logo
SHMUY
Shimizu
1.0$34.03-0.0%$6.53 billion$15.62 billion7.91
Tosoh logo
TOSCF
Tosoh
0.9$20.02-4.9%$6.50 billion$7.76 billion0.00Decrease in Short Interest
News Coverage
Gap Up
Howden Joinery Group logo
HWDJY
Howden Joinery Group
1.0$43.45-0.0%$6.49 billion$2.02 billion24.41
Grupo Carso logo
GPOVY
Grupo Carso
0.4$5.68-0.0%$6.48 billion$5.11 billion0.00Upcoming Earnings
Grupo Financiero Inbursa logo
GPFOY
Grupo Financiero Inbursa
0.0$4.87-0.0%$6.44 billionN/A0.00
OSRAM Licht logo
OSAGF
OSRAM Licht
0.5$61.00-0.0%$6.39 billion$3.41 billion-16.01
Renishaw logo
RNSHF
Renishaw
0.4$87.40-0.2%$6.36 billion$643.28 million136.56
H. Lundbeck A/S logo
HLUYY
H. Lundbeck A/S
0.9$30.27-4.7%$6.31 billion$2.55 billion23.65Analyst Revision
Gap Up
Bankinter logo
BKNIY
Bankinter
0.5$6.95-1.7%$6.25 billion$2.16 billion0.00Upcoming Earnings
Royal Vopak logo
VOPKY
Royal Vopak
1.5$49.82-1.5%$6.17 billion$1.40 billion15.87News Coverage
Nippon Yusen Kabushiki Kaisha logo
NPNYY
Nippon Yusen Kabushiki Kaisha
0.7$7.42-3.2%$6.10 billion$15.35 billion15.78
Jiangsu Expressway logo
JEXYY
Jiangsu Expressway
1.0$24.20-0.0%$6.10 billion$1.43 billion13.75Upcoming Earnings
boohoo group logo
BHOOY
boohoo group
0.8$95.00-0.0%$5.99 billion$1.58 billion63.33
MERLIN ENTERTAI/S logo
MERLY
MERLIN ENTERTAI/S
0.6$11.67-0.0%$5.97 billion$2.25 billion0.00
DS Smith logo
DITHF
DS Smith
1.0$5.50-0.0%$5.89 billion$7.65 billion13.10
Orion Oyj logo
ORINY
Orion Oyj
1.2$20.51-0.0%$5.79 billion$1.18 billion20.11Upcoming Earnings
Onex logo
ONEXF
Onex
1.8$62.84-1.7%$5.78 billion$1.11 billion17.41
BRTHY
Brother Industries
1.5$44.03-2.4%$5.77 billion$5.49 billion13.18News Coverage
Gap Up
COBHAM PLC/ADR logo
CBHMY
COBHAM PLC/ADR
0.7$4.49-0.0%$5.54 billion$2.18 billion40.82
Kimberly-Clark de México, S. A. B. de C. V. logo
KCDMY
Kimberly-Clark de México, S. A. B. de C. V.
1.0$9.10-2.0%$5.50 billion$2.26 billion19.36Upcoming Earnings
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.